Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. April 2017 08:00 ET | Quelle: Mustang Bio, Inc.

Mustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer

NEW YORK, April 24, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced that Manuel Litchman, M.D., has been appointed President and...
21. November 2016 08:30 ET | Quelle: Mustang Bio, Inc.

Clinical and Pre-Clinical Data on Mustang Bio’s MB-101 (IL13Rα2-specific CAR T cells) for the Treatment of Glioblastoma (GBM) Presented at the 21st Annual Meeting and Education Day of the Society for Neuro-Oncology

Phase 1 data suggests MB-101 is safe and well‐tolerated, capable of eliciting potent anti-tumor response NEW YORK, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”), a Fortress...
05. Mai 2016 09:52 ET | Quelle: Mustang Bio, Inc.

Mustang Bio Announces Oral Presentation of Initial Clinical Data for MB-101 (IL13Ra2-specific CAR T cells) by City of Hope Investigators at the American Society of Gene and Cell Therapy 19th Annual Meeting

NEW YORK, May 05, 2016 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced that an oral presentation related to its MB-101 (IL13Rα2-specific...
18. April 2016 12:06 ET | Quelle: Mustang Bio, Inc.

Mustang Bio Announces Presentations of MB-101, a Novel IL13Ra2-specific CAR-T cells Product in Clinical Development, at the American Society of Gene and Cell Therapy 19th Annual Meeting

NEW YORK, April 18, 2016 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced that two abstracts pertaining to its MB-101 (IL13Rα2-specific...

Vorherige Seite